drugset / Trial / NCT02796781
Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases
NaSingle-groupOpen-labelTreatment
Summary
Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The lung scarring that occurs in ILD is often irreversible with only mitigating therapy available so far. This study intends to carry out an open, single-armed, phase I/II clinical trial to investigate whether lung stem cells can regenerate damaged lung tissue. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. After careful characterization, cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.
Timeline
- Start
- 2016-10-12
- Primary completion
- 2020-08-31
- Completion
- 2020-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lung stem cells | Unknown | 500000 cells/kg | Other |
| Subject | Lung stem cells | Unknown | 5e+06 cells/kg | Other |